


CASE REPORT

Open Access



# Surgical resection of micronodular thymic carcinoma with lymphoid hyperplasia: a case report

Naoki Miyamoto<sup>1\*</sup> , Kazuya Kondo<sup>1</sup>, Yoshimi Bando<sup>2</sup>, Fuyumi Izaki<sup>1</sup>, Taihei Takeuchi<sup>1</sup>, Hiroyuki Sumitomo<sup>1</sup>, Shinichi Sakamoto<sup>1</sup>, Mika Takashima<sup>1</sup>, Naoya Kawakita<sup>1</sup>, Hiroaki Toba<sup>1</sup> and Hiromitsu Takizawa<sup>1</sup>

## Abstract

**Background** Micronodular thymic carcinoma with lymphoid hyperplasia is an extremely rare thymic tumor, exhibiting a variety of cell morphologies with mild to severe dysmorphism. Since few cases have been reported, the prognosis of this disease is unclear.

**Case presentation** A 55-year-old woman was referred to our hospital with an anterior mediastinal tumor. She was incidentally detected with a tumor in a medical examination. We diagnosed the patient with thymic carcinoma or thymoma and performed surgery via median sternotomy. Histologically, tumor cells showed weakly acidic vesicles and bright nuclei, including small nucleoli. Most of the tumor cells were cluster of differentiation (CD)5-positive, CD3-negative, and terminal deoxynucleotidyl transferase (TdT)-negative.

**Conclusions** Based on these histological findings, the resected specimen was diagnosed as micronodular thymic carcinoma with lymphoid hyperplasia. The patient's postoperative course was uneventful, and no signs of recurrence were observed at 5 years after the surgery.

**Keywords** Dysmorphism, Mediastinal tumor, Median sternotomy, Thymic carcinoma, Thymoma

## Background

Micronodular thymic carcinoma with lymphoid hyperplasia (MNC) is a thymic tumor characterized by lymphoid stroma and malignant components. Since MNC is extremely rare and its histological presentation is diverse, very few reports on MNC are currently available. Herein, we present the case of a patient diagnosed with MNC.

## Case presentation

A 55-year-old woman was referred to our hospital with an anterior mediastinal tumor. She was incidentally detected with the tumor in a medical examination. Chest computed tomography (CT) showed a 24-mm tumor in the anterior mediastinum (Fig. 1a). Since the patient had no dysphagia, dysarthria, or muscle weakness, she was followed up. The tumor size enlarged to 32 mm in 2 years (Fig. 1b). However, no abnormalities in blood biochemical findings were observed. The tumor markers, alpha-fetoprotein ([AFP], 5 ng/mL) and  $\beta$ -human chorionic gonadotrophin ([ $\beta$ -hCG], 0.88 ng/mL), were not elevated. Tumor positron emission tomography and CT (PET-CT) using F18-fluorodeoxyglucose (F18-FDG) revealed FDG accumulation and a maximum standardized uptake value of 25.2 by the tumor (Fig. 1c). Hence, we diagnosed the patient with thymic carcinoma or

\*Correspondence:


Naoki Miyamoto  
naoki.m.413@gmail.com

<sup>1</sup> Department of Thoracic, Endocrine Surgery and Oncology, Tokushima University Graduate School of Medical Science, 3-18-15, Kuramoto-cho, Tokushima 770-8503, Japan

<sup>2</sup> Department of Pathology, Tokushima University Hospital, Tokushima, Japan




© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



**Fig. 1** Chest computed tomography revealed a tumor in the anterior mediastinum (**a**). The tumor enlarged over a period of 2 years (**b**). PET-CT imaging revealed an FDG accumulation in the tumor (**c**). PET-CT positron emission tomography with computed tomography, FDG fluorodeoxyglucose

thymoma and performed surgery via median sternotomy. The tumor did not invade the surrounding area, and extended thymectomy was performed successfully. Histologically, the nodule in the resected specimen was covered with a capsule and consisted of small lymphocytes and island-shaped epithelioid cell follicles (Fig. 2a).

The nuclei of the epithelioid tumor cells were relatively large, and anisonucleosis and irregular edges were mild (Fig. 2b). Tumor cells contained weakly acidic vesicles and bright nuclei, including small nucleoli. Mitotic figures were seen in 2–3/10 high-power fields (HPF). Ki-67 expression in tumor nests was among 1–5%, and tumor



**Fig. 2** Histological examination revealed that the tumor consisted of small lymphocytes and island-shaped epithelioid cell follicles (**a**). The nuclei of epithelioid cells were oval and relatively large (**b**)




nodules were separated by abundant lymphoid stroma. The surrounding lymphoid stroma was composed of dense proliferation zones of small lymphocytes and contained some lymphoid follicles with germinal centers. Lymphocytes in the lymphoid stroma were a cluster of differentiation (CD)20-positive (Fig. 3a) and B-cell lymphoma 2 (Bcl2)-negative. Most of the tumor cells within the lymphoid stroma were CD5-positive (Fig. 3b), CD3-negative (Fig. 3c), and terminal deoxynucleotidyl transferase (TdT)-negative (Fig. 3d). Based on these histological findings, the resected specimen was diagnosed as MNC (pT1N0M0 stage I, Masaoka II). Since the tumor had been completely resected, we determined postoperative adjuvant chemotherapy as unnecessary. The patient's postoperative course was uneventful, and the patient was discharged 7 days postoperatively. No signs of recurrence were observed at 5 years after the surgery.

### Discussion and conclusions

MNC is a rare thymic tumor characterized by lymphoid aggregates and germinal centers. Unlike most thymic tumors that are characterized by T lymphocytic

infiltration, MNC forms germinal centers within the thymic cortex with a heavy infiltration of B lymphocytes. Micronodular thymomas with lymphoid stroma (MNT) were first described in 1999<sup>1</sup>, and MNC was more recently described as a malignant MNT counterpart<sup>2</sup>. These two types of tumors are collectively referred to as micronodular thymic tumors. The incidence of MNT is as low as approximately 5% of all thymoma cases, and the incidence of MNC is even lower. A PubMed search for publications in English using the keyword "Micronodular thymic carcinoma" identified a total of 13 patients with MNC<sup>2-6</sup>. In these reports, the patients' age range was 42–78 years; 8 patients were males and 5 were females. Among the 10 cases, eight cases mentioned tumor size of 1.1–10 cm, and no patient underwent a preoperative PET/CT scan. The treatment employed for twelve cases was surgical resection. Follow-up data were available for eleven cases, as one patient died of recurrence. Histologically, MNC displays a benign micronodular component similar to that of MNT, as well as a cancerous component. Regarding our case, an MNT diagnosis was excluded based on the following reasons: [1] most tumor



**Fig. 3** Histological immunostaining: lymphoid follicles were CD20-positive (a). Most tumor cells were CD5-positive (b), CD3-negative (c), and TdT-negative (d). CD cluster of differentiation, TdT terminal deoxynucleotidyl transferase

cells showed epithelioid morphology rather than spindle shape and [2] cell atypia and mitotic figures were easily identified.

Wang et al. established the criteria for the classification of micronodular thymic tumors<sup>4</sup>. They mentioned the following features of MNC: [1] tumor cells with moderate-to-severe dysplasia, [2] tumor cell mitotic figures > 2/10 HPF, [3] evidence of neoplastic necrosis, [4] no terminal deoxynucleotidyl transferase-positive immature T lymphocytes within the tumor, [5] tumor cells with a Ki-67 index  $\geq 10\%$ , and [6] tumor cells expressing CD5. In the present case, the Ki-67 index was less than 10%, but the tumor cell mitotic figures were approximately 2–3/10 HPF, and the tumor cells were expressing CD5, hence pointing to a diagnosis of MNC, based on the above criteria. The number of MNC cases reported is very small, and MNC is only mentioned as a differential diagnosis of MNT in the thymoma WHO classification 4th edition [7]. Moreover, MNC can exhibit a variety of cell morphologies, ranging from mild to severe dysmorphism. Although only one out of the 10 reported patients with MNC died, the prognosis of MNC remained unclear. The case presented here is considered a low-malignant type MNC with the following features: [1] no evident tumor necrosis and [2] a slight increase in mitotic figures.

In this case, we performed extended thymectomy via a median sternotomy. The fat around the resected thymus gland contained lymph nodes, but no lymph nodal metastasis was detected. There are no reports demonstrating the benefit of lymph node dissection or postoperative adjuvant chemotherapy for thymic epithelial tumors. Therefore, we consider that performing these procedures has little significance. At the time of this surgery, our surgical choice was a median sternotomy for thymic epithelial tumors and video-assisted thoracoscopic surgery (VATS) for small benign mediastinal tumors. In recent years, the use of VATS and robot-assisted thoracic surgery (RATS) for thymic epithelial tumors has increased, and their usefulness is reported [8, 9]. These surgeries are considered acceptable if complete resection can safely be performed. Although the tumor was completely resected and no recurrence occurred, preoperative PET-CT showed high FDG accumulation; therefore, careful follow-up was deemed necessary.

#### Abbreviations

AFP	Alpha-fetoprotein
Bcl2	B-cell lymphoma 2
CD	Cluster of differentiation
CT	Computed tomography
FDG	Fluorodeoxyglucose
HPF	High-power field
MNC	Micronodular thymic carcinoma with lymphoid hyperplasia
MNT	Micronodular thymomas with lymphoid stroma
PET	Positron emission tomography

TdT	Terminal deoxynucleotidyl transferase
WHO	World Health Organization
$\beta$ -hCG	$\beta$ -Human chorionic gonadotrophin.

#### Acknowledgements

None.

#### Authors' contributions

KK analyzed and interpreted the patient data regarding the MNC disease. YB performed the histological examination. FI, TT, HS, SS, MT, NK, and HT gave some advice and help to collect references for this article. HT was a major contributor in writing the manuscript. The authors read and approved the final manuscript.

#### Funding

None.

#### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

#### Declarations

#### Ethics approval and consent to participate

Our patient was fully informed about the publication, and informed consent was signed by the patient.

#### Consent for publication

Not applicable.

#### Competing interests

The authors declare that they have no competing interests.

Received: 19 September 2022 Accepted: 5 January 2023

Published online: 03 May 2023

#### References

- Suster S, Moran CA. Micronodular thymoma with lymphoid B-cell hyperplasia: clinicopathologic and immunohistochemical study of eighteen cases of a distinctive morphologic variant of thymic epithelial neoplasm. *Am J Surg Pathol*. 1999;23:955–62.
- Weissferdt A, Moran CA. Micronodular thymic carcinoma with lymphoid hyperplasia: a clinicopathological and immunohistochemical study of five cases. *Mod Pathol*. 2012;25:993–9.
- Mneimneh WS G-PY, Kesler KA, Loehrer PJ Sr, Badve S. Micronodular thymic neoplasms: case series and literature review with emphasis on the spectrum of differentiation. *Mod Pathol*. 2015;28:1415–27.
- Wang B, Li K, Song QK, Wang XH, Yang L, Zhang HL, et al. Micronodular thymic tumor with lymphoid stroma: a case report and review of the literature. *World J Clin Cases*. 2019;7:4063–74.
- Tateyama H, Saito Y, Fujii Y, Okumura M, Nakamura K, Tada H, et al. The spectrum of micronodular thymic epithelial tumours with lymphoid B-cell hyperplasia. *Histopathology*. 2001;38:519–27.
- Liu PP, Su YC, Niu Y, Shi YF, Luo J, Zhongcorresponding DR. Comparative clinicopathological and immunohistochemical study of micronodular thymoma and micronodular thymic carcinoma with lymphoid stroma. *J Clin Pathol*. 2022;10:702–5.
- Tateyama H, Marx A, Strobel P, et al. Micronodular thymoma with lymphoid stroma. In: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, editors. *WHO classification of tumours of the lung, pleura, thymus and heart*. 4th ed. Lyon: International Agency for Research on Cancer; 2015. p. 205–6.
- Xie A, Tjahjono R, Phan K, Yan TD. Video-assisted thoracoscopic surgery versus open thymectomy for thymoma: a systematic review. *Ann Cardiothorac Surg*. 2015;6:495–508.

9. Shen C, Li J, Li J, Che G. Robot-assisted thoracic surgery versus video-assisted thoracic surgery for treatment of patients with thymoma: a systematic review and meta-analysis. *Thorac Cancer*. 2022;2:151–61.

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

